Pooled Analysis of Use of Entrectinib in ROS1-Positive Lung Cancer
Posted: Tuesday, May 14, 2019
The ROS1 inhibitor entrectinib was found to be safe and effective in patients with ROS1-positive non–small cell lung cancer (NSCLC), according to the findings of a pooled analysis of the ALKA-372-001, STARTRK-1, and STARTRK-2 trials. Fabrice Barlesi, MD, PhD, of Marseille University in France, and colleagues observed high response rates and durable responses in this patient population. The findings were presented at the 2019 European Lung Cancer Congress (ELCC) in Geneva (Abstract 109O).
The three trials included 134 patients with locally advanced, metastatic NSCLC harboring a ROS1 fusion who had not received previous ROS1 treatment. At baseline, 43.4% of patients had central nervous system disease.
The overall response rate among the entire patient population was 77.4%. Of them, 3 patients (5.7%) achieved a complete response. Patients with central nervous system disease achieved an overall response rate of 73.9%, none complete responses. The median duration of response in the overall patient population was almost double that of patients with central nervous system disease (24.6 months vs. 12.6 months).
At least a single treatment-related adverse event was seen in 93% of the ROS1 safety-evaluable population. The most commonly reported adverse events were dysgeusia (42.5%), dizziness (32.8%), and constipation (32.8%). The most commonly reported grade 3 and 4 treatment-related adverse events included weight gain, diarrhea, increases in myalgia and aspartate aminotransferase, dysgeusia, dizziness, and increases in blood creatinine. Most adverse events were grade 1 and 2, and there were no grade 5 treatment-related adverse events.
Disclosure: The study authors’ disclosure information may be found at cslide.ctimeetingtech.com.
